Dyskinesia clinical trials at UCSD
1 research study open to eligible people
Showing trials for
Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II)
open to eligible people ages 40-75
To evaluate the safety and efficacy of transplantation of human induced pluripotent stem cell-derived dopaminergic progenitors, CT1-DAP001, into the corpus striatum in patients with Parkinson's disease
La Jolla, California
Our lead scientists for Dyskinesia research studies include Joseph Ciacci, MD.